UCB to purchase Neurona and NRTX-1001 for $1.15bn
UCB has agreed to acquire Neurona Therapeutics for up to $1.15 billion, expanding its epilepsy portfolio with NRTX-1001, a regenerative cell therapy. The deal marks UCB's entry into regenerative medicine and advanced treatments for epilepsy.
UCB has signed a definitive agreement to acquire Neurona Therapeutics for up to $1.15 billion. The deal includes an upfront payment of up to $650 million and up to $500 million in future milestones. NRTX-1001, Neurona's lead asset, is a regenerative cell therapy under investigation in Phase I/II trials for treating drug-resistant mesial temporal lobe epilepsy. The therapy involves a single brain dose of cells producing the inhibitory neurotransmitter GABA to rebalance neural circuits and reduce seizures. The acquisition is expected to close by the end of Q2 2026, pending customary conditions and anti-trust clearance. UCB's move into regenerative medicine reflects its strategy to diversify treatment offerings beyond symptomatic management.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.